Baylor College of Medicine

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (H-36160)

Description

Content

SS1: Pilot Study of Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (MDS)

This study will investigate the effects of sertraline in people with low-risk myelodysplastic syndrome (MDS). It is hoped that sertraline will decrease disease progression and reduce the need for blood transfusions.

For more information see Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (SS1).

Contact

Study Coordinator

IRB: H-36160

Status:

Active

Back to topback-to-top